Cristian Massacesi

5.2k total citations · 1 hit paper
67 papers, 2.4k citations indexed

About

Cristian Massacesi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Cristian Massacesi has authored 67 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 19 papers in Molecular Biology. Recurrent topics in Cristian Massacesi's work include Cancer Treatment and Pharmacology (28 papers), PI3K/AKT/mTOR signaling in cancer (15 papers) and HER2/EGFR in Cancer Research (15 papers). Cristian Massacesi is often cited by papers focused on Cancer Treatment and Pharmacology (28 papers), PI3K/AKT/mTOR signaling in cancer (15 papers) and HER2/EGFR in Cancer Research (15 papers). Cristian Massacesi collaborates with scholars based in Italy, United States and France. Cristian Massacesi's co-authors include Emmanuelle di Tomaso, Patrick Urban, M. Bonsignori, Samit Hirawat, Lucia Trandafir, Marco Rocchi, Daniele Santini, Giuseppe Tonini, Mario Campone and Nathalie Fretault and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Cristian Massacesi

66 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

2017 412 citations Alice T. Shaw, Tae Min Kim et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cristian Massacesi Italy	20	1.6k	1.1k	984	288	245	67	2.4k
Toshimi Takano Japan	25	2.1k 1.3×	1.7k 1.6×	628 0.6×	616 2.1×	89 0.4×	172	3.0k
Edda Simoncini Italy	26	1.7k 1.1×	753 0.7×	440 0.4×	1.1k 3.7×	170 0.7×	99	2.5k
J. Thaddeus Beck United States	19	1.4k 0.8×	740 0.7×	551 0.6×	619 2.1×	82 0.3×	74	2.1k
Martin Steins Germany	27	1.6k 0.9×	776 0.7×	939 1.0×	374 1.3×	283 1.2×	72	2.8k
Suneel Mundle United States	28	560 0.3×	1.5k 1.4×	913 0.9×	638 2.2×	398 1.6×	131	3.3k
Arlene Berman United States	22	1.3k 0.8×	474 0.4×	614 0.6×	534 1.9×	223 0.9×	47	2.4k
Jin‐Hee Ahn South Korea	25	938 0.6×	821 0.8×	549 0.6×	484 1.7×	122 0.5×	115	1.9k
Jolanda Paolini United States	16	2.7k 1.6×	3.1k 2.9×	999 1.0×	931 3.2×	82 0.3×	30	3.9k
Gladys Urbanowitz United States	8	2.0k 1.2×	2.2k 2.0×	1.9k 2.0×	996 3.5×	161 0.7×	12	4.2k
Maria Martinez‐García Spain	18	675 0.4×	389 0.4×	386 0.4×	318 1.1×	287 1.2×	81	1.3k

Countries citing papers authored by Cristian Massacesi

Since Specialization

Citations

This map shows the geographic impact of Cristian Massacesi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cristian Massacesi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cristian Massacesi more than expected).

Fields of papers citing papers by Cristian Massacesi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cristian Massacesi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cristian Massacesi. The network helps show where Cristian Massacesi may publish in the future.

Co-authorship network of co-authors of Cristian Massacesi

This figure shows the co-authorship network connecting the top 25 collaborators of Cristian Massacesi. A scholar is included among the top collaborators of Cristian Massacesi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cristian Massacesi. Cristian Massacesi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cabrera, Claudia, Zara Ghazoui, Victoria L. Chiou, et al.. (2024). Diversity of US participants in AstraZeneca-sponsored clinical trials. Contemporary Clinical Trials. 140. 107496–107496.

Shaw, Alice T., Tae Min Kim, Lucio Crinò, et al.. (2017). Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology. 18(7). 874–886. 412 indexed citations breakdown →

Pistilli, Barbara, Timothy Pluard, Ander Urruticoechea, et al.. (2017). Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. Breast Cancer Research and Treatment. 168(2). 357–364. 50 indexed citations

Martín, Miguel, Luc Dirix, Joyce O’Shaughnessy, et al.. (2016). A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4). Annals of Oncology. 28(2). 313–320. 136 indexed citations

Leo, Angelo Di, Eva Ciruelos, Wolfgang Janni, et al.. (2015). BELLE-3: A Phase III study of the pan-phosphatidylinositol 3-kinase (PI3K) inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced/metastatic breast cancer (BC) pretreated with aromatase inhibitors (AIs) and refractory to mTOR inhibitor (mTORi)-based treatment.. Journal of Clinical Oncology. 33. 5 indexed citations

Saura, Cristina, Johanna C. Bendell, Guy Jérusalem, et al.. (2014). Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy. Clinical Cancer Research. 20(7). 1935–1945. 110 indexed citations

Rodón, Jordi, Irene Braña, Lillian L. Siu, et al.. (2014). Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Investigational New Drugs. 32(4). 670–681. 151 indexed citations

Massacesi, Cristian, Emmanuelle di Tomaso, Nathalie Fretault, & Samit Hirawat. (2013). Challenges in the clinical development of PI3K inhibitors. Annals of the New York Academy of Sciences. 1280(1). 19–23. 34 indexed citations

Wen, Patrick Y., W. K. Alfred Yung, Ingo K. Mellinghoff, et al.. (2013). Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM).. Journal of Clinical Oncology. 31(15_suppl). 2015–2015. 4 indexed citations

10.

André, Fabrice, Mario Campone, Ruth O’Regan, et al.. (2010). Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab. Journal of Clinical Oncology. 28(34). 5110–5115. 148 indexed citations

11.

Massacesi, Cristian, Annalisa La Cesa, F. Marcucci, et al.. (2006). Capecitabine and Mitomycin C Is an Effective Combination for Anthracycline- and Taxane-Resistant Metastatic Breast Cancer. Oncology. 70(4). 294–300. 17 indexed citations

12.

Massacesi, Cristian, Luciano Burattini, F. Marcucci, & M. Bonsignori. (2005). Short Communication: The Efficacy of Fixed Dose Rate Infusion of Gemcitabine Combined with IFN-α2a in Patients with Advanced Refractory Renal Cell Carcinoma. Journal of Interferon & Cytokine Research. 25(3). 165–168. 6 indexed citations

13.

Mattioli, Rodolfo, Cristian Massacesi, F. Recchia, et al.. (2005). High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Annals of Oncology. 16(7). 1147–1151. 40 indexed citations

14.

Santini, Daniele, Cristian Massacesi, Rolando Maria D’Angelillo, et al.. (2004). Raltitrexed plus Weekly Oxaliplatin as First-Line Chemotherapy in Metastatic Colorectal Cancer: A Multicenter Non-randomized Phase II Study. Medical Oncology. 21(1). 59–66. 15 indexed citations

15.

Massacesi, Cristian, et al.. (2004). Factors Predicting Docetaxel-Related Toxicity: Experience at a Single Institution. Journal of Chemotherapy. 16(1). 85–93. 8 indexed citations

16.

Santini, Daniele, Bruno Vincenzi, Cristian Massacesi, et al.. (2004). S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury.. PubMed. 23(6D). 5173–9. 32 indexed citations

17.

Massacesi, Cristian, Daniele Santini, Marco Rocchi, et al.. (2003). Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors. Anti-Cancer Drugs. 14(7). 533–541. 9 indexed citations

18.

Lippe, P., Rodolfo Mattioli, Cristian Massacesi, et al.. (2002). Clinical benefit of gemcitabine-cisplatin in advanced non-small cell lung cancer elderly patients.. PubMed. 22(2B). 1053–9. 8 indexed citations

19.

Mazzanti, Paola, Cristian Massacesi, Rodolfo Mattioli, et al.. (2001). Gemcitabine-cisplatin (GP) vs gemcitabine-carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a multicenter phase II randomized trial. European Journal of Cancer. 37. S50–S50. 7 indexed citations

20.

Lippe, P., et al.. (2000). Assessing clinical benefit (CB) of chemotherapy (CT) in advanced non-small cell lung cancer elderly patients. Lung Cancer. 29(1). 34–34. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact